Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077

被引：37

作者：

Landovitz, Raphael J. ^{[1
,2
]}

Zangeneh, Sahar Z. ^{[3
]}

Chau, Gordon ^{[3
]}

Grinsztejn, Beatriz ^{[4
]}

Eron, Joseph J. ^{[5
]}

Dawood, Halima ^{[6
]}

Magnus, Manya ^{[7
]}

Liu, Albert Y. ^{[8
]}

Panchia, Ravindre ^{[9
]}

Hosseinipour, Mina C. ^{[10
]}

Kofron, Ryan ^{[1
,2
]}

Margolis, David A. ^{[11
]}

Rinehart, Alex ^{[11
]}

Adeyeye, Adeola ^{[12
]}

Burns, David ^{[12
]}

McCauley, Marybeth ^{[13
]}

Cohen, Myron S. ^{[5
]}

Currier, Judith S. ^{[1
,2
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Ctr AIDS Res & Educ, Dept Med,Div Infect Dis, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, David Geffen Sch Med, Ctr HIV Prevent, Los Angeles, CA 90095 USA

[3] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA

[4] Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas INI, Lab HIV, Rio De Janeiro, Brazil

[5] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA

[6] Univ KwaZulu Natal, Dept Med, Durban, South Africa

[7] George Washington Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Milken Inst, Washington, DC USA

[8] San Francisco Dept Publ Hlth, Populat Hlth Div, Bridge HIV, San Francisco, CA USA

[9] Univ Witwatersrand, Perinatal HIV Res Unit, Chris Hani Baragwanath Acad Hosp, Soweto, South Africa

[10] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC 27515 USA

[11] ViiV Healthcare, Res Triangle Pk, Durham, NC USA

[12] NIAID, Div AIDS, NIH, Rockville, MD USA

[13] FHI 360, Sci Facilitat Dept, FHI 360, Washington, DC USA

来源：

CLINICAL INFECTIOUS DISEASES | 2020年 / 70卷 / 02期

基金：

美国国家卫生研究院;

关键词：

cabotegravir; CAB; weight gain; HIV uninfected; DOLUTEGRAVIR; THERAPY; ADULTS;

D O I：

10.1093/cid/ciz439

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.

引用

页码：319 / 322

页数：4

共 50 条

[31] Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans
Sutton, S. S.
Magagnoli, Joseph
Cummings, Tammy H.
Hardin, James W.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2021, 21 (01) : 103 - 112
[32] The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment
Kamal, Susan
Locatelli, Isabella
Wandeler, Gilles
Sehhat, Asemaneh
Bugnon, Olivier
Metral, Melanie
Du Pasquier, Renaud
Gutbrod, Klemens
Cavassini, Matthias
Schneider, Marie P.
OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (02):
[33] Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
Riestenberg, Robert A.
Furman, Andrew
Cowen, Avery
Pawlowksi, Anna
Schneider, Daniel
Lewis, Alana A.
Kelly, Sean
Taiwo, Babafemi
Aehenbach, Chad
Palella, Frank
Stone, Neil J.
Lloyd-Jones, Donald M.
Feinstein, Matthew J.
AMERICAN HEART JOURNAL, 2019, 209 : 79 - 87
[34] Human immunodeficiency virus associated thrombotic thrombocytopenic purpura, a clinical conundrum
Warner, Nathaniel C.
Vaughan, Leroy B.
Wenzel, Richard P.
JOURNAL OF CLINICAL APHERESIS, 2017, 32 (06) : 567 - 570
[35] Human Immunodeficiency Virus-Associated Tuberculosis Update on Prevention and Treatment
Dierberg, Kerry L.
Chaisson, Richard E.
CLINICS IN CHEST MEDICINE, 2013, 34 (02) : 217 - +
[36] Long-Acting Cabotegravir Plus Rilpivirine in People With Human Immunodeficiency Virus With Adherence Challenges and Viremia: Current Data and Future Directions
Davis, Jennifer M.
Rana, Aadia
Sax, Paul E.
Bares, Sara H.
CLINICAL INFECTIOUS DISEASES, 2024,
[37] Managing Human Immunodeficiency Virus-associated Tuberculosis in the Dolutegravir Era
Maartens, Gary
Meintjes, Graeme
CLINICAL INFECTIOUS DISEASES, 2020, 70 (04) : 557 - 558
[38] Dietary Intervention Prevents Dyslipidemia Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Individuals
Lazzaretti, Rosmeri K.
Kuhmmer, Regina
Sprinz, Eduardo
Polanczyk, Carisi A.
Ribeiro, Jorge P.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (11) : 979 - 988
[39] Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children
Dreimane, D
Nielsen, K
Deveikis, A
Bryson, YJ
Geffner, ME
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (03) : 315 - 316
[40] A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants
LaCourse, Sylvia M.
Richardson, Barbra A.
Kinuthia, John
Warr, A. J.
Maleche-Obimbo, Elizabeth
Matemo, Daniel
Cranmer, Lisa M.
Mecha, Jerphason
Escudero, Jaclyn N.
Hawn, Thomas R.
John-Stewart, Grace
CLINICAL INFECTIOUS DISEASES, 2021, 73 (02) : E337 - E344

← 1 2 3 4 5 →